Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 300-340-2 | CAS number: 93925-38-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Toxicokinetic assessment using physico-chemical properties and toxicological study data.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Toxicokinetic assessment using reliable physico-chemical properties and toxicological study data.
Data source
Materials and methods
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- The toxicokinetic profile of the test item was predicted using the physical chemical properties of the substance, the data obtained from acute and repeated-dose toxicity studies, as well as information gained from genotoxicity assays.
Test material
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- The test item is a UVCB with an average molecular weight of 238. The substance is poorly water soluble at 5.4 x 10-4g/L, with an estimated octanol/water partition coefficient, log Pow>3.42, and a low vapour pressure (9.6 x 10-4Pa @ 25°C). The surface tension of the substance has not been determined because of the low water solubility and the substance is considered not to dissociate at environmental pH.
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- - Oral Route: The physical chemical properties described above indicate that the substance has a molecular size which may be expected to be absorbed within the mammalian gastrointestinal tract, should that material be ingested. Being lipophilic with a Log Pow of >3.42, the substance may be expected to cross gastrointestinal epithelial barriers, and the evidence from the repeated dose toxicity study indicates that absorption did occur because there were dose-related increases in liver organ weights. An acute oral gavage toxicity study identified no evidence of toxicity (LD50 >2000 mg/kg bw). The repeat dose and reproductive screening toxicology study using the oral route gave a NOAEL of 750 mg/kg bw/day. The absence of adverse findings following oral dosing is probably due to a low index of inherent toxicity for this substance, and/or its metabolite(s).- Dermal Route: Regarding the dermal absorption of the substance, its rate of uptake into the stratum corneum and its rate of transfer between the stratum corneum and the epidermis are likely to be slow considering the MW, the log Pow, and its low water solubility. These assumptions were supported by the absence of observed systemic effects following dermal application of the substance in the acute dermal toxicity study at up to 2000 mg/kg bw.- Inhalation Route: The potential for inhalation toxicity was not studied directly in a toxicology study using the inhalation route. However, the physical nature of the substance (a liquid) with a low vapour pressure (9.6 x 10-4Pa) that indicates a very low propensity to enter atmospheric air in a respirable form. Thus, respiratory absorption under normal use, and based on the life-cycle information of this substance, is expected to be inconsequential.
- Details on distribution in tissues:
- Systemic distribution of the substance can be predicted from the physical chemical properties of this substance. The log Pow and poor water solubility suggests that this substance, upon systemic absorption, may be transported through the circulatory system in association with a carrier molecule such as a lipoprotein or other macromolecules. The lipophilic character and MW of the substance suggests that a major proportion of the substance will readily traverse cellular barriers and distribute into fatty tissues. There is evidence of systemic exposure and histopathological changes in repeated dose studies, but not of cumulative toxicity, as would be manifested by an accumulation of the substance or metabolites in tissues.
- Details on excretion:
- The characteristics of the substance suggest that this molecule may undergo phase I and phase II metabolic transformation. The resulting metabolic by-products are expected to undergo routine renal and or biliary excretion.
Metabolite characterisation studies
- Details on metabolites:
- The substance is a UVCB and like most xenobiotics, it may be expected to undergo phase I oxidation/reduction, esterase-catalyzed hydrolysis and subsequent Phase II conjugation. Acute and repeated-dose toxicity testing provided no evidence that the substance was metabolized into toxic metabolites. Data from bacterial mutagenicity and a chromosomal aberration test in mammalian cells, in which the substance was subjected to rat hepatic microsomal enzyme systems did not show any evidence of genotoxic activity from the substance or its metabolites. Furthermore, the in vitro toxicity of the substance was slightly reduced in the presence of metabolic enzymes. This may indicate that the metabolites may be less toxic than the substance itself but more likely that the presence of protein may bind the substance, or protect the cells, such that the toxicity is reduced.
Applicant's summary and conclusion
- Conclusions:
- The toxicokinetic profile of the test item was predicted using the physical chemical properties of the substance, the data obtained from acute and repeated-dose toxicity studies, as well as information gained from genotoxicity assays.- Physico-chemical properties: the test item is a UVCB with an average molecular weight of 238. The substance is poorly water soluble at 5.4 x 10-4g/L, with an estimated octanol/water partition coefficient, log Pow>3.42, and a low vapour pressure (9.6 x 10-4Pa @ 25°C). The surface tension of the substance has not been determined because of the low water solubility and the substance is considered not to dissociate at environmental pH.Absorption- Oral Route: The physical chemical properties described above indicate that the substance has a molecular size which may be expected to be absorbed within the mammalian gastrointestinal tract, should that material be ingested. Being lipophilic with a Log Pow of >3.42, the substance may be expected to cross gastrointestinal epithelial barriers, and the evidence from the repeated dose toxicity study indicates that absorption did occur because there were dose-related increases in liver organ weights. An acute oral gavage toxicity study identified no evidence of toxicity (LD50 >2000 mg/kg bw). The repeat dose and reproductive screening toxicology study using the oral route gave a NOAEL of 750 mg/kg bw/day. The absence of adverse findings following oral dosing is probably due to a low index of inherent toxicity for this substance, and/or its metabolite(s).- Dermal Route: Regarding the dermal absorption of the substance, its rate of uptake into the stratum corneum and its rate of transfer between the stratum corneum and the epidermis are likely to be slow considering the MW, the log Pow, and its low water solubility. These assumptions were supported by the absence of observed systemic effects following dermal application of the substance in the acute dermal toxicity study at up to 2000 mg/kg bw.- Inhalation Route: The potential for inhalation toxicity was not studied directly in a toxicology study using the inhalation route. However, the physical nature of the substance (a liquid) with a low vapour pressure (9.6 x 10-4Pa) that indicates a very low propensity to enter atmospheric air in a respirable form. Thus, respiratory absorption under normal use, and based on the life-cycle information of this substance, is expected to be inconsequential. DistributionSystemic distribution of the substance can be predicted from the physical chemical properties of this substance. The log Pow and poor water solubility suggests that this substance, upon systemic absorption, may be transported through the circulatory system in association with a carrier molecule such as a lipoprotein or other macromolecules. The lipophilic character and MW of the substance suggests that a major proportion of the substance will readily traverse cellular barriers and distribute into fatty tissues. There is evidence of systemic exposure and histopathological changes in repeated dose studies, but not of cumulative toxicity, as would be manifested by an accumulation of the substance or metabolites in tissues. MetabolismThe substance is a UVCB and like most xenobiotics, it may be expected to undergo phase I oxidation/reduction, esterase-catalyzed hydrolysis and subsequent Phase II conjugation. Acute and repeated-dose toxicity testing provided no evidence that the substance was metabolized into toxic metabolites. Data from bacterial mutagenicity and a chromosomal aberration test in mammalian cells, in which the substance was subjected to rat hepatic microsomal enzyme systems did not show any evidence of genotoxic activity from the substance or its metabolites. Furthermore, the in vitro toxicity of the substance was slightly reduced in the presence of metabolic enzymes. This may indicate that the metabolites may be less toxic than the substance itself but more likely that the presence of protein may bind the substance, or protect the cells, such that the toxicity is reduced. ExcretionThe characteristics of the substance suggest that this molecule may undergo phase I and phase II metabolic transformation. The resulting metabolic by-products are expected to undergo routine renal and or biliary excretion.
- Executive summary:
The toxicokinetic profile of the test item was predicted using the physical chemical properties of the substance, the data obtained from acute and repeated-dose toxicity studies, as well as information gained from genotoxicity assays.
- Physico-chemical properties: The test item is a UVCB with an average molecular weight of 238. The substance is poorly water soluble at 5.4 x 10-4g/L, with an estimated octanol/water partition coefficient, log Pow>3.42, and a low vapour pressure (9.6 x 10-4Pa @ 25°C). The surface tension of the substance has not been determined because of the low water solubility and the substance is considered not to dissociate at environmental pH.
Absorption
- Oral Route: The physical chemical properties described above indicate that the substance has a molecular size which may be expected to be absorbed within the mammalian gastrointestinal tract, should that material be ingested. Being lipophilic with a Log Pow of >3.42, the substance may be expected to cross gastrointestinal epithelial barriers, and the evidence from the repeated dose toxicity study indicates that absorption did occur because there were dose-related increases in liver organ weights. An acute oral gavage toxicity study identified no evidence of toxicity (LD50 >2000 mg/kg bw). The repeat dose and reproductive screening toxicology study using the oral route gave a NOAEL of 750 mg/kg bw/day. The absence of adverse findings following oral dosing is probably due to a low index of inherent toxicity for this substance, and/or its metabolite(s).
- Dermal Route: Regarding the dermal absorption of the substance, its rate of uptake into the stratum corneum and its rate of transfer between the stratum corneum and the epidermis are likely to be slow considering the MW, the log Pow, and its low water solubility. These assumptions were supported by the absence of observed systemic effects following dermal application of the substance in the acute dermal toxicity study at up to 2000 mg/kg bw.
- Inhalation Route: The potential for inhalation toxicity was not studied directly in a toxicology study using the inhalation route. However, the physical nature of the substance (a liquid) with a low vapour pressure (9.6 x 10-4Pa) that indicates a very low propensity to enter atmospheric air in a respirable form. Thus, respiratory absorption under normal use, and based on the life-cycle information of this substance, is expected to be inconsequential.
Distribution
Systemic distribution of the substance can be predicted from the physical chemical properties of this substance. The log Pow and poor water solubility suggests that this substance, upon systemic absorption, may be transported through the circulatory system in association with a carrier molecule such as a lipoprotein or other macromolecules. The lipophilic character and MW of the substance suggests that a major proportion of the substance will readily traverse cellular barriers and distribute into fatty tissues. There is evidence of systemic exposure and histopathological changes in repeated dose studies, but not of cumulative toxicity, as would be manifested by an accumulation of the substance or metabolites in tissues.
Metabolism
The substance is a UVCB and like most xenobiotics, it may be expected to undergo phase I oxidation/reduction, esterase-catalyzed hydrolysis and subsequent Phase II conjugation. Acute and repeated-dose toxicity testing provided no evidence that the substance was metabolized into toxic metabolites. Data from bacterial mutagenicity and a chromosomal aberration test in mammalian cells, in which the substance was subjected to rat hepatic microsomal enzyme systems did not show any evidence of genotoxic activity from the substance or its metabolites. Furthermore, the in vitro toxicity of the substance was slightly reduced in the presence of metabolic enzymes. This may indicate that the metabolites may be less toxic than the substance itself but more likely that the presence of protein may bind the substance, or protect the cells, such that the toxicity is reduced.
Excretion
The characteristics of the substance suggest that this molecule may undergo phase I and phase II metabolic transformation. The resulting metabolic by-products are expected to undergo routine renal and or biliary excretion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies